Diabetic Retinopathy: COLIRIOBCN070660 Eye Drops

We are studying a new eye drop treatment for people with moderately severe to severe diabetic retinopathy. The goal is to see if it can reduce eye damage and improve vision.

1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesEndocrinologyOphthalmology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Somatostatin
Somatostatin is a substance that reduces the release of many hormones to help control hormone overproduction and some hormone-secreting tumors.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

ColirioBCN070660

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Clinic De Barcelona
Retina
Amorebieta, Spain
Hospital De La Santa Creu I Sant Pau
Retina
Barbastro, Spain
Institut Catala De Retina S.L.
Retinal Department
Barcelona, Spain
Sponsor: Bcn Peptides S.A.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.